Overview

An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments

Status:
Completed
Trial end date:
2014-04-10
Target enrollment:
0
Participant gender:
All
Summary
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:

- Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)

- Previously prescribed any IOP-lowering therapy which has been stopped and a new
prostaglandin analogue -containing IOP-lowering therapy started

Exclusion Criteria:

- None